272 related articles for article (PubMed ID: 6715398)
61. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas.
Riopel MA; Ronnett BM; Kurman RJ
Am J Surg Pathol; 1999 Jun; 23(6):617-35. PubMed ID: 10366144
[TBL] [Abstract][Full Text] [Related]
62. Endometrioid proliferative and low malignant potential tumors of the ovary. A clinicopathologic study of 46 cases.
Snyder RR; Norris HJ; Tavassoli F
Am J Surg Pathol; 1988 Sep; 12(9):661-71. PubMed ID: 3414893
[TBL] [Abstract][Full Text] [Related]
63. [Pitfalls and common problems in the differential diagnosis of epithelial ovarian tumors].
Lax SF
Pathologe; 2019 Feb; 40(1):46-60. PubMed ID: 30719693
[TBL] [Abstract][Full Text] [Related]
64. Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Jin JS; Hsieh DS; Loh SH; Chen A; Yao CW; Yen CY
Mod Pathol; 2006 Mar; 19(3):447-52. PubMed ID: 16439987
[TBL] [Abstract][Full Text] [Related]
65. Recurrent endocervical-like mucinous borderline tumor (ELMBT) arising in a case of long-standing endometriosis--a case report.
Srinivasan R; Gupta N; Gupta I
Indian J Pathol Microbiol; 2006 Apr; 49(2):277-8. PubMed ID: 16933740
[TBL] [Abstract][Full Text] [Related]
66. Hyaline globules in ovarian tumours.
al-Nafussi AI; Hughes DE; Williams AR
Histopathology; 1993 Dec; 23(6):563-6. PubMed ID: 7508880
[TBL] [Abstract][Full Text] [Related]
67. Clinicopathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors: an institutional perspective.
Hashmi AA; Hussain ZF; Bhagwani AR; Edhi MM; Faridi N; Hussain SD; Khan M
BMC Res Notes; 2016 Apr; 9():205. PubMed ID: 27052022
[TBL] [Abstract][Full Text] [Related]
68. Frequency of papillary tubal hyperplasia (PTH), salpingoliths and transition from adenoma to borderline ovarian tumors (BOT): A systematic analysis of 74 BOT with different histologic types.
Horn LC; Angermann K; Hentschel B; Einenkel J; Höhn AK
Pathol Res Pract; 2017 Apr; 213(4):305-309. PubMed ID: 28238382
[TBL] [Abstract][Full Text] [Related]
69. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
70. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
71. Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: an immunocytochemical study of eighty-three cases.
Viale G; Gambacorta M; Dell'Orto P; Coggi G
Virchows Arch A Pathol Anat Histopathol; 1988; 413(2):91-101. PubMed ID: 2455381
[TBL] [Abstract][Full Text] [Related]
72. Incidence of serous tubal intraepithelial carcinoma (STIC) by algorithm classification in serous ovarian tumor associated with PAX8 expression in tubal epithelia: a study of single institution in Japan.
Munakata S; Yamamoto T
Int J Gynecol Pathol; 2015 Jan; 34(1):9-18. PubMed ID: 25473747
[TBL] [Abstract][Full Text] [Related]
73. Benign endometrioid tumours of the ovary and the Müllerian concept of ovarian epithelial tumours.
Hughesdon PE
Histopathology; 1984 Nov; 8(6):977-90. PubMed ID: 6526392
[TBL] [Abstract][Full Text] [Related]
74. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
75. Periodic acid-Schiff stain as a prognostic indicator in serous and mucinous ovarian tumors.
Aalto ML; Collan Y
Int J Gynaecol Obstet; 1986 Feb; 24(1):27-34. PubMed ID: 2874066
[TBL] [Abstract][Full Text] [Related]
76. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm.
Taylor J; McCluggage WG
Am J Surg Pathol; 2015 Jul; 39(7):983-92. PubMed ID: 25723110
[TBL] [Abstract][Full Text] [Related]
77. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
78. Ovarian carcinomas, including secondary tumors: diagnostically challenging areas.
Prat J
Mod Pathol; 2005 Feb; 18 Suppl 2():S99-111. PubMed ID: 15492758
[TBL] [Abstract][Full Text] [Related]
79. Recent concepts of ovarian carcinogenesis: type I and type II.
Koshiyama M; Matsumura N; Konishi I
Biomed Res Int; 2014; 2014():934261. PubMed ID: 24868556
[TBL] [Abstract][Full Text] [Related]
80. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma.
Leitao MM; Boyd J; Hummer A; Olvera N; Arroyo CD; Venkatraman E; Baergen RN; Dizon DS; Barakat RR; Soslow RA
Am J Surg Pathol; 2004 Feb; 28(2):147-59. PubMed ID: 15043303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
